Thursday, April 30, 2015

Gilead Hepatitis Drugs Brought In $4.55 Billion in First Quarter by ANDREW POLLACK


By ANDREW POLLACK

Sales of Harvoni and an earlier hepatitis C drug, Sovaldi, far exceeded Wall Street expectations and made the company one of the top earners in pharmaceuticals.

Published: May 1, 2015 at 12:00AM

from NYT Business Day http://ift.tt/1OJR0uD



from WordPress http://ift.tt/1JVnL1h
via Hadi Aboukhater
Posted by at
Labels: , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)